We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

114 hedge funds and large institutions have $247M invested in BioSpecifics Technologies Corp. in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 34

0% more funds holding

Funds holding: 114114 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

5% less capital invested

Capital invested by funds: $259M → $247M (-$12.3M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
114
Holders Change
Holders Change %
0%
% of All Funds
2.5%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
12
Increased
40
Reduced
34
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of Montreal
51
Bank of Montreal
Ontario, Canada
$850K +$778K +13,368 +533%
SG Americas Securities
52
SG Americas Securities
New York
$645K +$702K +12,052 New
VRS
53
Virginia Retirement Systems
Virginia
$642K -$774K -13,300 -53%
SO
54
STRS Ohio
Ohio
$567K
Swiss National Bank
55
Swiss National Bank
Switzerland
$546K
BCM
56
Bridgeway Capital Management
Texas
$526K
California State Teachers Retirement System (CalSTRS)
57
California State Teachers Retirement System (CalSTRS)
California
$505K
State of Wisconsin Investment Board
58
State of Wisconsin Investment Board
Wisconsin
$492K +$87.3K +1,500 +19%
MERSOM
59
Municipal Employees' Retirement System of Michigan
Michigan
$471K
MPAM
60
Monarch Partners Asset Management
Massachusetts
$457K +$58.8K +1,010 +13%
CI
61
Cavalier Investments
Georgia
$417K
Two Sigma Advisers
62
Two Sigma Advisers
New York
$412K -$81.5K -1,400 -15%
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$405K -$4.37K -75 -1%
AllianceBernstein
64
AllianceBernstein
Tennessee
$380K +$69.9K +1,200 +20%
D.E. Shaw & Co
65
D.E. Shaw & Co
New York
$362K
CIBC Private Wealth Group
66
CIBC Private Wealth Group
Georgia
$357K -$38.9K -669 -9%
New York State Common Retirement Fund
67
New York State Common Retirement Fund
New York
$353K -$162K -2,784 -30%
BPM
68
Bowling Portfolio Management
Ohio
$335K -$12.9K -222 -3%
MF
69
Manchester Financial
California
$327K
Ohio Public Employees Retirement System (OPERS)
70
Ohio Public Employees Retirement System (OPERS)
Ohio
$289K -$195K -3,346 -38%
WA
71
Winfield Associates
Ohio
$268K +$291K +5,000 New
AIMCA
72
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$262K
PCM
73
Perritt Capital Management
Illinois
$262K
Victory Capital Management
74
Victory Capital Management
Texas
$247K +$185K +3,173 +219%
Macquarie Group
75
Macquarie Group
Australia
$246K

BSTC Hedge Fund Activity: Q3 2019 in Review

114 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q3 2019, worth a combined $247M — down 4.7% from $259M a quarter earlier.

Fund positioning in BSTC was balanced in Q3 2019: 12 funds opened new positions, 12 closed out, 40 added to existing stakes and 34 trimmed.

The largest buyer was Royce & Associates, adding an estimated $9.38M. The largest seller was Millennium Management, cutting an estimated $4.66M.

  • 114 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $247M of BioSpecifics Technologies Corp. stock for Q3 2019, down 4.7% quarter-over-quarter.
  • 12 funds opened new BioSpecifics Technologies Corp. positions in Q3 2019 and 12 closed out, a net change of 0 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q3 2019 was Royce & Associates, an estimated $9.38M added.
  • The largest BioSpecifics Technologies Corp. seller in Q3 2019 was Millennium Management, an estimated $4.66M sold.

Based on aggregated 13F filings for Q3 2019.